US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Missfresh Limited

1.00

+0.0000

Volume:- -

Turnover:- -

Market Cap:7.77M

PE:-0.03

High:1.00

Open:1.00

Low:1.00

Close:1.00

Loading ...

Overview Company News Filings

Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome

Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services

Geron Corporation (GERN) Stock: An Under $5 Gem with Biggest Upside Potential

Incyte Gains 15.3% in a Year: Is There Room for Further Growth?

Disc Medicine Highlights Recent Achievements Across Hematology Portfolio and Key Business Objectives and Milestones for 2025

Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025

Why GERN Stock (GERN) is Skyrocketing

Is Geron Corporation (GERN) the Best Penny Stock to Buy for 2025?

Top Crypto Projects for Growth in Blockchain and DeFi

Why Is Geron Corporation (GERN) Among the Best Biotech Penny Stocks to Invest in Now?

Is Geron Corporation (GERN) the Best NASDAQ Penny Stock to Buy Right Now?

Positive Clinical Updates and Promising Therapeutic Potential for Elritercept in MDS and MF: A Strong Case for Continued Development

Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis

Clinical trial data for MF candidate proves promising for Syntara

The Market Herald

Keros Therapeutics Presents Clinical Data from its Elritercept Program at the 66th American Society of Hematology Annual Meeting and Exposition

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MF/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"MF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MF\",,,,,undefined,":{"symbol":"MF","market":"US","secType":"STK","nameCN":"Missfresh Limited","latestPrice":1,"timestamp":1743192000000,"preClose":1,"halted":4,"volume":0,"delay":0,"floatShares":5586728,"shares":7772983,"eps":-28.707302,"marketStatus":"Delisted","change":0,"latestTime":"03-31 05:26:55 EDT","open":1,"high":1,"low":1,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-28.707302,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1743427800000},"marketStatusCode":1,"adr":0,"adrRate":90,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":1,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MF\",,,,,undefined,":{"symbol":"MF","floatShares":5586728,"roa":"-44.95%","roe":"-2003.66%","lyrEps":-28.663709,"shares":7772983,"dividePrice":0,"high":1,"amplitude":0,"preClose":1,"low":1,"week52Low":0.4111,"pbRate":"-0.04","psRate":"0.02","week52High":3.28,"institutionHeld":0,"latestPrice":1,"eps":-28.707302,"divideRate":0,"volume":0,"delay":0,"ttmEps":-28.707302,"open":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MF\",pageSize:16,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2512990300","title":"Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2512990300","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512990300?lang=en_us&edition=fundamental","pubTime":"2025-02-17 14:02","pubTimestamp":1739772120,"startTime":"0","endTime":"0","summary":"Designation is based on TELLOMAK Phase 2 results demonstrating efficacy and a favorable safety profile in patients with advanced Sézary syndrome heavily pre-treated, post- mogamulizumab.Breakthrough Therapy Designation is intended to accelerate the development and regulatory review in the U.S. of drugs that are intended to treat a serious condition; adding to a Fast Track designation by the U.S. FDA received in 2019 as well as a PRIME designation by European Medicines Agency in 2020. Innate continues to align with regulatory agencies around the confirmatory Phase 3 trial in Cutaneous T Cell Lymphoma and is actively seeking for a partner. Innate Pharma SA   today announced that the U.S. Food and Drug Administration  has granted Breakthrough Therapy Designation  to lacutamab, an anti-KIR3DL2 cytotoxicity-inducing antibody, for the treatment of adult patients with relapsed or refractory (r/r) Sézary Syndrome  after at least 2 prior systemic therapies including mogamulizumab.Cutaneous T-Ce","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/innate-pharma-announces-u-fda-060200389.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","IPHA","BK4563","BK4231","IPHYF","BK4080","BK4539","BK4526","BK4113","MF","ADC"],"gpt_icon":0},{"id":"2509027926","title":"Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services","url":"https://stock-news.laohu8.com/highlight/detail?id=2509027926","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509027926?lang=en_us&edition=fundamental","pubTime":"2025-02-06 21:55","pubTimestamp":1738850100,"startTime":"0","endTime":"0","summary":"Permanent J-Code  expected to be effective April 1, 2025. LYMPHIR is approved by the U.S. Food and Drug Administration  for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma  after at least one prior systemic therapy.CRANFORD, N.J., Feb. 6, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc.   and its oncology-focused subsidiary, Citius Oncology, Inc.  , today announced that LYMPHIR  has been assigned a unique, permanent Healthcare Common Procedure Coding System  J-code  by the Centers for Medicare & Medicaid Services .Effective April 1, 2025, healthcare providers may use the permanent J-code, J9161 , when submitting claims for LYMPHIR.\"The establishment of a permanent J-code marks a critical milestone in supporting patient access to LYMPHIR, providing coding clarity for physicians and facilities who administer LYMPHIR, and facilitating reimbursement. This achievement is a key step in ensuring that LYMPHIR is accessible to patients with com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/citius-pharmaceuticals-citius-oncology-announce-135500837.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/citius-pharmaceuticals-citius-oncology-announce-135500837.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2637428348.USD","BK4588","CTOR","BK4526","BK4539","LU2346227817.USD","LU2125910500.SGD","BK4145","LU2045819591.USD","BK4139","LU1894683348.USD","BK4208","BK4113","CMS","CTXR","BK4585","LU1894683264.USD","MF","BK4563"],"gpt_icon":1},{"id":"2505260950","title":"Geron Corporation (GERN) Stock: An Under $5 Gem with Biggest Upside Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2505260950","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505260950?lang=en_us&edition=fundamental","pubTime":"2025-01-21 11:02","pubTimestamp":1737428547,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 12 Stocks Under $5 With Biggest Upside Potential.In this article, we are going to take a look at where Geron Corporation  stands against other stocks under $5 with biggest upside potential.On January 20, Bloomberg reported that relief swept through the markets as it became clear that Donald Trump would not immediately impose China-specific tariffs on his first day in office, sparking a rally in US equity futures and a decline in the dollar.According to people familiar with the plans, the Trump administration is pivoting towards a more engagement-oriented approach with Beijing, rather than pursuing another trade war.The administration also plans to issue a memorandum directing federal agencies to study existing trade policies and relationships with China, Canada, and Mexico, rather than imposing new tariffs.Despite the positive economic indicators, Druckenmiller noted that the earnings yield to bond yield i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geron-corporation-gern-stock-under-030227751.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NQmain","BK4563","MF","USJW.SI","GERN","QID","TQQQ","QLD",".IXIC","SQQQ","NVIW.SI","USAW.SI","TSYW.SI","BK4087","BK4139","CHMP","BK4539","BK4113","MNQmain","BK4526","PSQ"],"gpt_icon":1},{"id":"2505255268","title":"Incyte Gains 15.3% in a Year: Is There Room for Further Growth?","url":"https://stock-news.laohu8.com/highlight/detail?id=2505255268","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505255268?lang=en_us&edition=fundamental","pubTime":"2025-01-21 03:35","pubTimestamp":1737401700,"startTime":"0","endTime":"0","summary":"Shares of Incyte INCY have risen 15.3% in the past twelve months against the industry’s decline of 14.3%. The stock has outperformed the sector but lagged S&P 500 during this time frame.The outperformance can be attributed to new drug approvals and recent pipeline progress. Lead drug Jakafi  also maintains momentum.At the recently held J.P. Morgan Healthcare Conference, management highlighted that 2025 will be a transformational year for INCY with four potential launches.Jakafi is marketed by Incyte in the United States and by Novartis NVS as Jakavi in ex-U.S. markets. Incyte earns royalties from NVS on sales outside the country.Incyte and partner Syndax Pharmaceuticals obtained FDA approval for axatilimab-csfr, an anti-CSF-1R antibody, for the treatment of GVHD after the failure of at least two prior lines of systemic therapy in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/incyte-gains-15-3-room-193500040.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4578","IE00BJT1NW94.SGD","IE0009355771.USD","GSK","MF","BK4526","BK4585","BK4007","IE00B2B36J28.USD","BK4563","LU0211331839.USD","NVS","IE00B4R5TH58.HKD","BK4139","BK4113","GSK.UK","IE0002141913.USD","BK4532","IE00BFTCPJ56.SGD","BK4588","BK4550","IE00BJJMRZ35.SGD","BK4539","LU1829250122.USD","INCY"],"gpt_icon":1},{"id":"2502861204","title":"Disc Medicine Highlights Recent Achievements Across Hematology Portfolio and Key Business Objectives and Milestones for 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2502861204","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502861204?lang=en_us&edition=fundamental","pubTime":"2025-01-10 22:00","pubTimestamp":1736517600,"startTime":"0","endTime":"0","summary":"In Q1 2025, the Company will discuss the plans for NDA submission under a potential accelerated approval path for bitopertin in erythropoietic protoporphyria (EPP), following a Type C meeting with FDA","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/10/3007729/0/en/Disc-Medicine-Highlights-Recent-Achievements-Across-Hematology-Portfolio-and-Key-Business-Objectives-and-Milestones-for-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MF","BK4539","BK4563","IRON","BK4139","BK4526","BK4582","BK4113","EPP"],"gpt_icon":0},{"id":"2501012832","title":"Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2501012832","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501012832?lang=en_us&edition=fundamental","pubTime":"2025-01-07 21:08","pubTimestamp":1736255280,"startTime":"0","endTime":"0","summary":"CRANFORD, N.J., Jan. 7, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc.   and its oncology-focused subsidiary, Citius Oncology , today announced significant progress in preparations for the commercial launch of LYMPHIR, an innovative immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma . Management is focused on making LYMPHIR available to patients as quickly as possible, with preparations underway for launch in the first half of 2025.\"Since LYMPHIR's approval in August 2024, we have worked diligently toward supporting its successful launch. We are making significant progress to finalize our manufacturing, marketing, reimbursement and sales efforts. This is a pivotal inflection point as we transition from clinical development to revenue generation. Our strategy not only focuses on a successful U.S. market penetration, but also includes exploring additional growth opportunities, including licensing partnerships in key international markets, f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/citius-pharmaceuticals-citius-oncology-highlight-130800989.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/citius-pharmaceuticals-citius-oncology-highlight-130800989.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4539","BK4139","BK4145","CLS","LU2045819591.USD","BK4563","BK4113","BK4588","BK4526","LU2125910500.SGD","CTXR","BK4585","CTOR","MF"],"gpt_icon":0},{"id":"2500594801","title":"Why GERN Stock (GERN) is Skyrocketing","url":"https://stock-news.laohu8.com/highlight/detail?id=2500594801","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500594801?lang=en_us&edition=fundamental","pubTime":"2025-01-02 16:50","pubTimestamp":1735807829,"startTime":"0","endTime":"0","summary":"A lackluster trading persisted throughout the last day of the year, with Wall Street’s main indices ending the day mixed.The Dow Jones Industrial Average dipped by 0.07 percent, the S&P 500 shed 0.43 percent, and the Nasdaq Composite declined by 0.90 percent. Meanwhile, NYSE Composite inched up by 0.10 percent and S&P Composite rose by 0.44 percent.Geron Corp.  rose for a third day on Wednesday, ending the year stronger by 4.12 percent at $3.54 apiece. Year-to-date, the company eked out gains of 65.4 percent from the $2.14 registered on January 2, 2024.Overall, GERN ranks 7th on our list of firms end 2024 stronger with impressive gains. While we acknowledge the potential of GERN as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than GERN but that trades at less than 5 times its earnings, check out our report about the ch","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-gern-stock-gern-skyrocketing-085029623.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["QLD","MNQmain","BK4526","USJW.SI","MF","BK4113","GERN","BK4539","USAW.SI","SQQQ","NQmain",".IXIC","QID","PSQ","TSYW.SI","NVIW.SI","BK4139","BK4563","TQQQ"],"gpt_icon":1},{"id":"2500893459","title":"Is Geron Corporation (GERN) the Best Penny Stock to Buy for 2025?","url":"https://stock-news.laohu8.com/highlight/detail?id=2500893459","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500893459?lang=en_us&edition=fundamental","pubTime":"2025-01-01 19:58","pubTimestamp":1735732736,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 Best Penny Stocks to Buy for 2025.In this article, we are going to take a look at where Geron Corporation  stands against the other penny stocks.The US stock market has been on a roll owing to a powerful rally in the technology sector. The S&P 500 has gained more than 23%, driven by gains in mega-cap stocks amid the artificial intelligence frenzy. Likewise, the gains have come amid a resilient US economy that has steered clear of recession. Improving monetary policy outlook on the US Federal Reserve cutting interest rate has also strengthened investor sentiments on equities.While small-cap stocks have lagged behind the overall market, they are drawing special attention as most appear to be trading at highly discounted valuations. Often considered speculative investments due to their low price point and smaller market presence, penny stocks are turning out to be attractive investment plays heading into 2025.READ ALSO: 10 Best Stocks to Buy According","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geron-corporation-gern-best-penny-115856453.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NVIW.SI","BK4563","BK4588","TQQQ","USAW.SI","GERN","MF","QID","QLD","USJW.SI","BK4539","BK4526","BK4585",".IXIC","MAA","MNQmain","BK4139","BK4113","BK4215","NQmain","PSQ","TSYW.SI","SQQQ"],"gpt_icon":1},{"id":"2500237896","title":"Top Crypto Projects for Growth in Blockchain and DeFi","url":"https://stock-news.laohu8.com/highlight/detail?id=2500237896","media":"CoinMarketCap","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500237896?lang=en_us&edition=fundamental","pubTime":"2025-01-01 05:49","pubTimestamp":1735681763,"startTime":"0","endTime":"0","summary":"As the blockchain gaming and decentralized finance  sectors continue to grow, these platforms are poised to capitalize on the upcoming bull market.Aureal One’s focus on Zero-Knowledge Rollups and gaming, combined with DexBoss’s advanced trading features, makes them ideal picks for investors gearing up for the next major rally. Let’s explore why these tokens could dominate the next crypto bull run.DexBoss  is revolutionizing decentralized finance  by creating a platform that integrates traditional finance with the ever-evolving DeFi ecosystem. Supporting over 2,000 cryptocurrencies, it offers users a robust and comprehensive trading experience.The presale aims to raise $50 million, allocating 50% of the 1 billion tokens for this phase. Looking ahead, DexBoss plans to introduce advanced features, such as derivatives trading and expanded fiat integrations, by 2025 for the next crypto bull run. These additions will further enhance its usability and establish DexBoss as a key player in the ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://coinmarketcap.com/community/articles/677466e54b617205bff5519e/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"coinmarketcap_highlight","symbols":["BK4113","TON.USD.CC","BK4563","RNDR.USD.HKCC","MEME","TON.USD.HKCC","BK4526","MF","APT.USD.HKCC","BK4539","APT.USD.CC"],"gpt_icon":0},{"id":"2500430896","title":"Why Is Geron Corporation (GERN) Among the Best Biotech Penny Stocks to Invest in Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2500430896","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500430896?lang=en_us&edition=fundamental","pubTime":"2025-01-01 01:54","pubTimestamp":1735667646,"startTime":"0","endTime":"0","summary":"We recently published a list of the 12 Best Biotech Penny Stocks To Invest In Now. In this article, we are going to take a look at where Geron Corporation  stands against the other best biotech penny stocks to invest in now.Recent performance data supports Goldman’s outlook. The iShares Biotech ETF climbed 7.7% in Q3, outperforming the Nasdaq Biotech Index and more than doubling the S&P 500’s 3.2% gain over the same period. For investors anticipating a continued decline in bond yields, Goldman suggests biotechnology stocks may offer more attractive exposure compared to other rate-sensitive equity sectors, which are more dependent on broader economic growth trends.Sears noted that small and emerging biotechnology companies have been at the forefront of this innovation. In 2023, approximately two-thirds of all clinical trials were initiated by small and emerging biotechnology firms, and about 56% of new drug substances approved by regulatory bodies originated from these smaller compa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-geron-corporation-gern-among-175406307.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4139","GERN","IE0004086264.USD","LU2237443549.SGD","SQQQ","TSYW.SI","BK4563","LU1791807156.HKD","BK4127","BK4113","LU0106831901.USD","IE0034235188.USD","QID","NVIW.SI","BK4533","QLD","PSQ","BK4588","BK4504","USJW.SI","MF","BK4539","LU2237438978.USD","LU2237443895.HKD","TQQQ","BK4087","IE00BFXG1179.USD","LU2237443622.USD","CHMP","IE00B19Z3B42.SGD","LU2237443382.USD","LU2237443978.SGD","IE00B19Z3581.USD","IE0004091025.USD","BK4516","IE00BSNM7G36.USD","LU1668664300.SGD","IE0002270589.USD","MNQmain","USAW.SI","LU2237443465.HKD","BK4526",".IXIC","BK4552","NQmain","BK4550"],"gpt_icon":1},{"id":"2490884017","title":"Is Geron Corporation (GERN) the Best NASDAQ Penny Stock to Buy Right Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2490884017","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490884017?lang=en_us&edition=fundamental","pubTime":"2024-12-11 15:15","pubTimestamp":1733901319,"startTime":"0","endTime":"0","summary":"We recently published a list of 11 Best NASDAQ Penny Stocks To Buy Right Now. In this article, we are going to look at whereGeron Corporation  stands against other best NASDAQ penny stocks to buy right now.The NASDAQ Stock Market is home to some of the world’s largest companies in the world and also hosts several hundred penny stocks. These companies must meet certain requirements to remain listed on the NASDAQ exchange, including the $1 per share minimum share price thresholds, revenue standards, and market capitalization thresholds. If a company fails to meet these requirements, it may receive noncompliance notifications and eventually be delisted. According to a report by Bloomberg, this year’s market rally has boosted many of the struggling stocks, helping some companies regain compliance with NASDAQ’s listing requirements.A scientist holding a vial of the cancer-fighting drug developed by the biotechnology c","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/UE8z81ALQ980dMHJDG..6g--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/86de9186db0cafa46e5d387cfff70682","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/UE8z81ALQ980dMHJDG..6g--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/86de9186db0cafa46e5d387cfff70682"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geron-corporation-gern-best-nasdaq-071519389.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","MF","US6M.BOND","MAA","US3Y.BOND","IE00BGHQF748.EUR","US5Y.BOND","MNQmain","US12M.BOND","PSQ","BK4215","BK4563","US30Y.BOND","BK4585","BK4112","NQmain","LU2210150020.SGD","US10Y.BOND","BK4113","QID","SQQQ","BK4588","US7Y.BOND","US2Y.BOND","TQQQ","LU2210149790.SGD",".IXIC","IE00BKPKM429.USD","IE00B3QW5Z07.USD","GERN","QLD","NDAQ","LU2095319765.USD","IE00B64PRP62.GBP","BK4539","BK4526"],"gpt_icon":1},{"id":"2490894048","title":"Positive Clinical Updates and Promising Therapeutic Potential for Elritercept in MDS and MF: A Strong Case for Continued Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2490894048","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490894048?lang=en_us&edition=fundamental","pubTime":"2024-12-11 00:05","pubTimestamp":1733846746,"startTime":"0","endTime":"0","summary":"Wedbush analyst Yun Zhong has maintained their bullish stance on KROS stock, giving a Buy rating yesterday. Yun Zhong’s rating is based on promisin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/positive-clinical-updates-and-promising-therapeutic-potential-for-elritercept-in-mds-and-mf-a-strong-case-for-continued-development?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/positive-clinical-updates-and-promising-therapeutic-potential-for-elritercept-in-mds-and-mf-a-strong-case-for-continued-development?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4526","BK4113","BK4539","KROS","MF","BK4139","BK4563"],"gpt_icon":0},{"id":"2490176110","title":"Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2490176110","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490176110?lang=en_us&edition=fundamental","pubTime":"2024-12-10 22:00","pubTimestamp":1733839200,"startTime":"0","endTime":"0","summary":"In the dose escalation Part 1 of the study, no dose-limiting toxicities were observed and the PK profiles were similar to those reported for previous monotherapy studies of imetelstat and ruxolitinib. Based on the safety profile, imetelstat 9.4 mg/kg dosed every four weeks with ruxolitinib was the selected dose for the dose expansion Part 2 of the study, which is currently enrolling patients. \"Upon diagnosis, intermediate-1 and -2 and high-risk myelofibrosis patients typically receive ruxolitinib as the primary therapy, which reduces enlarged spleens and alleviates symptoms. These early results showing the tolerability of ruxolitinib combined with imetelstat in this patient population are highly encouraging, because as a non-JAK inhibitor treatment option with a potentially novel mechanism of action, imetelstat could provide an additive benefit, affecting the underlying malignant clones implicated in MF progression, when combined with ruxolitinib alone,\" said John Mascarenhas, M.D., Pr","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/pWJZ1mBrontFIBsPmSBvIQ--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/552cac5071faa71fd5f09cac7f030e72","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/pWJZ1mBrontFIBsPmSBvIQ--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/552cac5071faa71fd5f09cac7f030e72"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geron-announces-phase-1-findings-140000504.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4539","BK4181","HR","LU2463526074.USD","BK4563","MF","BK4109","BK4139","GERN","BK4225","BK4526","PK","TSS","BK4218","BK4113","ASH","BK4203"],"gpt_icon":0},{"id":"2490051521","title":"Clinical trial data for MF candidate proves promising for Syntara","url":"https://stock-news.laohu8.com/highlight/detail?id=2490051521","media":"The Market Herald","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490051521?lang=en_us&edition=fundamental","pubTime":"2024-12-10 13:08","pubTimestamp":1733807280,"startTime":"0","endTime":"0","summary":"Syntara Ltd  has reported interim data from a trial to assess the efficacy of its drug candidate for treatment of myelofibrosis , with results showing that the candidate – SNT-5505 – showed strong tolerability and improvements in both spleen volume and symptoms of the condition over time.The data – to be presented at the 66th American Society of Hematology annual meeting  – was from Syntara’s Phase 2 clinical trial for the drug, which was tested in combination with ruxolitinib .It showed a 50% improvement in Total Symptom Score  among 46% of evaluable patients following 12 weeks of treatment, with this rising to an 80% improvement at 38 weeks of treatment.TSS50 is a standard efficacy endpoint used as the primary endpoint in clinical trials related to MF.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investme","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/clinical-trial-data-for-mf-candidate-proves-promising-for-syntara-2024-12-10/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK4526","MF","SRV.AU","BK4113","BK7164","ASH.AU","BK7096","BK4563","SNT.AU","ASH","BK7057","BK4109","LU2463526074.USD","BK4539","BK7133","SRV"],"gpt_icon":0},{"id":"2490380550","title":"Keros Therapeutics Presents Clinical Data from its Elritercept Program at the 66th American Society of Hematology Annual Meeting and Exposition","url":"https://stock-news.laohu8.com/highlight/detail?id=2490380550","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490380550?lang=en_us&edition=fundamental","pubTime":"2024-12-10 08:30","pubTimestamp":1733790600,"startTime":"0","endTime":"0","summary":"Elritercept demonstrated a durable transfusion independence in lower-risk myelodysplastic syndromes, including in patients with high transfusion burden, with a median duration of response of 134.1 wee","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/10/2994148/0/en/Keros-Therapeutics-Presents-Clinical-Data-from-its-Elritercept-Program-at-the-66th-American-Society-of-Hematology-Annual-Meeting-and-Exposition.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4113","BK4539","AFG","MF","LENZ","BK4526","BK4117","BK4563","BK4107","BK4139"],"gpt_icon":0}],"pageSize":16,"totalPage":3,"pageCount":1,"totalSize":40}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MF\",params:#limit:5,,,undefined,":[{"market":"US","date":"2022-10-17","symbol":"MF","defaultRemindTime":1666013400000,"type":"split","dateTimestamp":1665979200000,"forFactor":30,"toFactor":1,"ratio":30},{"market":"US","date":"2021-11-11","symbol":"MF","fiscalQuarterEnding":"2021/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1636606800000,"reportTimeType":"post","actualEps":-0.66},{"market":"US","date":"2021-08-26","symbol":"MF","fiscalQuarterEnding":"2021/06","expectedEps":-2.16,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1629950400000,"reportTimeType":"post","actualEps":-5.48}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MF\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MF\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MF\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MF","date":"2023-11-16","current":-0.03539,"percent":0.648601,"low":-32.11263,"twenty":-1.865237,"median":-0.069098,"eighty":-0.028106,"high":-0.008193,"avg":-0.938264,"sd":2.296797,"marketCap":7384333},"quantilePoints":[{"date":"2021-06-25","current":-7.110902,"twenty":-32.106975,"median":-32.098493,"eighty":-17.105939,"marketCap":2274463661},{"date":"2021-07-02","current":-6.338927,"twenty":-22.103457,"median":-6.51424,"eighty":-6.371352,"marketCap":2022530316},{"date":"2021-07-09","current":-5.592526,"twenty":-6.992819,"median":-6.372013,"eighty":-5.926166,"marketCap":1782369560},{"date":"2021-07-16","current":-5.984077,"twenty":-6.517989,"median":-6.0717,"eighty":-5.522099,"marketCap":1907158976},{"date":"2021-07-23","current":-4.944161,"twenty":-6.481456,"median":-5.907476,"eighty":-5.522099,"marketCap":1575172037},{"date":"2021-07-30","current":-4.118662,"twenty":-6.373995,"median":-5.860853,"eighty":-5.032259,"marketCap":1316175139},{"date":"2021-08-06","current":-3.651632,"twenty":-6.362753,"median":-5.549376,"eighty":-4.15531,"marketCap":1163131522},{"date":"2021-08-13","current":-3.545136,"twenty":-6.285482,"median":-5.501154,"eighty":-3.834435,"marketCap":1130168282},{"date":"2021-08-20","current":-3.298913,"twenty":-6.054175,"median":-5.164407,"eighty":-3.617928,"marketCap":1047760174},{"date":"2021-08-27","current":-2.247676,"twenty":-5.971821,"median":-4.231883,"eighty":-3.568741,"marketCap":1097205034},{"date":"2021-09-03","current":-2.06394,"twenty":-5.916667,"median":-4.129113,"eighty":-3.426663,"marketCap":1010087896},{"date":"2021-09-10","current":-2.084402,"twenty":-5.892157,"median":-3.92974,"eighty":-3.298913,"marketCap":1021860486},{"date":"2021-09-17","current":-2.033597,"twenty":-5.889782,"median":-3.772314,"eighty":-2.118927,"marketCap":993606276},{"date":"2021-09-24","current":-2.091421,"twenty":-5.860853,"median":-3.625571,"eighty":-2.091421,"marketCap":1021860486},{"date":"2021-10-01","current":-2.008209,"twenty":-5.592526,"median":-3.584663,"eighty":-2.084402,"marketCap":984188209},{"date":"2021-10-08","current":-1.920987,"twenty":-5.555677,"median":-3.565065,"eighty":-2.049887,"marketCap":941806901},{"date":"2021-10-15","current":-1.827187,"twenty":-5.543074,"median":-3.490033,"eighty":-2.028961,"marketCap":897071071},{"date":"2021-10-22","current":-1.798685,"twenty":-5.516855,"median":-3.34385,"eighty":-2.008209,"marketCap":890007519},{"date":"2021-10-29","current":-1.885702,"twenty":-5.501154,"median":-3.29115,"eighty":-1.950409,"marketCap":930034311},{"date":"2021-11-05","current":-1.893294,"twenty":-5.384903,"median":-2.15964,"eighty":-1.927796,"marketCap":934743349},{"date":"2021-11-12","current":-1.893111,"twenty":-5.384653,"median":-2.115775,"eighty":-1.926255,"marketCap":1083077937},{"date":"2021-11-19","current":-1.870877,"twenty":-4.944161,"median":-2.102864,"eighty":-1.907244,"marketCap":1068950831},{"date":"2021-11-26","current":-2.164917,"twenty":-4.600679,"median":-2.092748,"eighty":-1.910043,"marketCap":1236121554},{"date":"2021-12-03","current":-1.847004,"twenty":-4.288468,"median":-2.091421,"eighty":-1.910043,"marketCap":1057178241},{"date":"2021-12-10","current":-1.902408,"twenty":-4.221007,"median":-2.08155,"eighty":-1.900585,"marketCap":1090141481},{"date":"2021-12-17","current":-1.809835,"twenty":-4.15531,"median":-2.065507,"eighty":-1.892014,"marketCap":1035987591},{"date":"2021-12-23","current":-1.668547,"twenty":-4.127023,"median":-2.061006,"eighty":-1.877223,"marketCap":955933999},{"date":"2021-12-31","current":-2.053249,"twenty":-4.061267,"median":-2.053333,"eighty":-1.865237,"marketCap":1179613142},{"date":"2022-01-07","current":-1.921377,"twenty":-3.911087,"median":-2.049887,"eighty":-1.870717,"marketCap":1099559557},{"date":"2022-01-14","current":-1.803334,"twenty":-3.834945,"median":-2.033783,"eighty":-1.865237,"marketCap":1035987591},{"date":"2022-01-21","current":-1.312737,"twenty":-3.809281,"median":-2.02988,"eighty":-1.849351,"marketCap":755800036},{"date":"2022-01-28","current":-1.140833,"twenty":-3.724041,"median":-2.024208,"eighty":-1.816776,"marketCap":654555793},{"date":"2022-02-04","current":-1.255738,"twenty":-3.646303,"median":-2.012315,"eighty":-1.801982,"marketCap":720482273},{"date":"2022-02-11","current":-1.254691,"twenty":-3.628119,"median":-1.999947,"eighty":-1.777804,"marketCap":720482273},{"date":"2022-02-18","current":-1.114148,"twenty":-3.606924,"median":-1.961463,"eighty":-1.755207,"marketCap":642783203},{"date":"2022-02-25","current":-0.774362,"twenty":-3.595381,"median":-1.947993,"eighty":-1.721983,"marketCap":447358278},{"date":"2022-03-04","current":-0.827555,"twenty":-3.583604,"median":-1.938892,"eighty":-1.663136,"marketCap":477966995},{"date":"2022-03-11","current":-0.654366,"twenty":-3.576713,"median":-1.927974,"eighty":-1.510894,"marketCap":376722760},{"date":"2022-03-18","current":-0.656616,"twenty":-3.565676,"median":-1.926255,"eighty":-1.319719,"marketCap":376722760},{"date":"2022-03-25","current":-0.603653,"twenty":-3.560264,"median":-1.922921,"eighty":-1.272248,"marketCap":346114035},{"date":"2022-04-01","current":-0.422795,"twenty":-3.534115,"median":-1.914317,"eighty":-1.239112,"marketCap":242515270},{"date":"2022-04-08","current":-0.574772,"twenty":-3.47419,"median":-1.908994,"eighty":-1.204604,"marketCap":329632415},{"date":"2022-04-14","current":-0.452551,"twenty":-3.41082,"median":-1.905066,"eighty":-1.198285,"marketCap":258996897},{"date":"2022-04-22","current":-0.388816,"twenty":-3.3472,"median":-1.902408,"eighty":-1.093833,"marketCap":218263743},{"date":"2022-04-29","current":-0.21999,"twenty":-3.3405,"median":-1.893203,"eighty":-0.827555,"marketCap":121493086},{"date":"2022-05-06","current":-0.12872,"twenty":-3.298913,"median":-1.887625,"eighty":-0.801811,"marketCap":70470693},{"date":"2022-05-13","current":-0.126121,"twenty":-3.29115,"median":-1.876165,"eighty":-0.773724,"marketCap":67810091},{"date":"2022-05-20","current":-0.099135,"twenty":-2.247676,"median":-1.857377,"eighty":-0.656616,"marketCap":54059709},{"date":"2022-05-27","current":-0.067857,"twenty":-2.188119,"median":-1.849938,"eighty":-0.616576,"marketCap":36965915},{"date":"2022-06-03","current":-0.107464,"twenty":-2.173465,"median":-1.837741,"eighty":-0.602219,"marketCap":58886472},{"date":"2022-06-10","current":-0.123657,"twenty":-2.165894,"median":-1.809835,"eighty":-0.571443,"marketCap":67268553},{"date":"2022-06-17","current":-0.103563,"twenty":-2.152566,"median":-1.805486,"eighty":-0.521169,"marketCap":56272961},{"date":"2022-06-24","current":-0.117384,"twenty":-2.131147,"median":-1.799883,"eighty":-0.456871,"marketCap":64042868},{"date":"2022-07-01","current":-0.119492,"twenty":-2.117036,"median":-1.779206,"eighty":-0.404522,"marketCap":65078854},{"date":"2022-07-08","current":-0.178553,"twenty":-2.114885,"median":-1.775229,"eighty":-0.374437,"marketCap":97359285},{"date":"2022-07-15","current":-0.16618,"twenty":-2.112791,"median":-1.757551,"eighty":-0.311835,"marketCap":89754194},{"date":"2022-07-22","current":-0.126228,"twenty":-2.104622,"median":-1.730681,"eighty":-0.172576,"marketCap":68233904},{"date":"2022-07-29","current":-0.050085,"twenty":-2.094065,"median":-1.696083,"eighty":-0.163245,"marketCap":27100490},{"date":"2022-08-05","current":-0.080486,"twenty":-2.092997,"median":-1.661783,"eighty":-0.147283,"marketCap":43440839},{"date":"2022-08-12","current":-0.078297,"twenty":-2.090283,"median":-1.647621,"eighty":-0.137047,"marketCap":42381307},{"date":"2022-08-19","current":-0.057132,"twenty":-2.086906,"median":-1.419538,"eighty":-0.133244,"marketCap":30585172},{"date":"2022-08-26","current":-0.055552,"twenty":-2.08212,"median":-1.330192,"eighty":-0.127899,"marketCap":29502095},{"date":"2022-09-02","current":-0.049858,"twenty":-2.078456,"median":-1.292716,"eighty":-0.126164,"marketCap":26370590},{"date":"2022-09-09","current":-0.05116,"twenty":-2.075575,"median":-1.270969,"eighty":-0.12294,"marketCap":26959219},{"date":"2022-09-16","current":-0.048796,"twenty":-2.065194,"median":-1.255215,"eighty":-0.118547,"marketCap":25475874},{"date":"2022-09-23","current":-0.039638,"twenty":-2.063353,"median":-1.222255,"eighty":-0.116313,"marketCap":20295934},{"date":"2022-09-30","current":-0.039015,"twenty":-2.060974,"median":-1.20685,"eighty":-0.110557,"marketCap":20013392},{"date":"2022-10-07","current":-0.046815,"twenty":-2.059361,"median":-1.202242,"eighty":-0.107298,"marketCap":24016075},{"date":"2022-10-14","current":-0.028297,"twenty":-2.053383,"median":-1.161027,"eighty":-0.103114,"marketCap":14362548},{"date":"2022-10-21","current":-0.039236,"twenty":-2.053249,"median":-1.093833,"eighty":-0.097648,"marketCap":19777925},{"date":"2022-10-28","current":-0.025268,"twenty":-2.052577,"median":-0.866249,"eighty":-0.080655,"marketCap":12714380},{"date":"2022-11-04","current":-0.025026,"twenty":-2.047365,"median":-0.807298,"eighty":-0.076479,"marketCap":12714380},{"date":"2022-11-11","current":-0.025067,"twenty":-2.036617,"median":-0.802612,"eighty":-0.070361,"marketCap":12871348},{"date":"2022-11-18","current":-0.02472,"twenty":-2.033895,"median":-0.792119,"eighty":-0.067938,"marketCap":13365796},{"date":"2022-11-25","current":-0.024416,"twenty":-2.033597,"median":-0.773724,"eighty":-0.058896,"marketCap":13106799},{"date":"2022-12-02","current":-0.02261,"twenty":-2.0308,"median":-0.678708,"eighty":-0.055552,"marketCap":12400445},{"date":"2022-12-09","current":-0.033064,"twenty":-2.028961,"median":-0.654366,"eighty":-0.053501,"marketCap":18296935},{"date":"2022-12-16","current":-0.033686,"twenty":-2.028804,"median":-0.624845,"eighty":-0.052591,"marketCap":18600667},{"date":"2022-12-23","current":-0.028061,"twenty":-2.024208,"median":-0.603653,"eighty":-0.05116,"marketCap":15461314},{"date":"2022-12-30","current":-0.033224,"twenty":-2.018429,"median":-0.598643,"eighty":-0.05004,"marketCap":13976173},{"date":"2023-01-06","current":-0.035525,"twenty":-2.016647,"median":-0.576755,"eighty":-0.048778,"marketCap":15075423},{"date":"2023-01-13","current":-0.038857,"twenty":-2.011494,"median":-0.548181,"eighty":-0.043844,"marketCap":16802815},{"date":"2023-01-20","current":-0.036341,"twenty":-2.006489,"median":-0.524812,"eighty":-0.043618,"marketCap":15546530},{"date":"2023-01-27","current":-0.037268,"twenty":-2.002325,"median":-0.488901,"eighty":-0.041046,"marketCap":15939119},{"date":"2023-02-03","current":-0.032209,"twenty":-1.988961,"median":-0.437673,"eighty":-0.039418,"marketCap":13819138},{"date":"2023-02-10","current":-0.032054,"twenty":-1.969539,"median":-0.405847,"eighty":-0.038855,"marketCap":13662102},{"date":"2023-02-17","current":-0.033081,"twenty":-1.962196,"median":-0.385085,"eighty":-0.037617,"marketCap":13976173},{"date":"2023-02-24","current":-0.031059,"twenty":-1.956322,"median":-0.366417,"eighty":-0.036834,"marketCap":12955441},{"date":"2023-03-03","current":-0.030277,"twenty":-1.949443,"median":-0.321666,"eighty":-0.035859,"marketCap":12719888},{"date":"2023-03-10","current":-0.03035,"twenty":-1.944681,"median":-0.205389,"eighty":-0.035042,"marketCap":12719888},{"date":"2023-03-17","current":-0.024225,"twenty":-1.940658,"median":-0.168591,"eighty":-0.034739,"marketCap":10207317},{"date":"2023-03-24","current":-0.023789,"twenty":-1.936956,"median":-0.164967,"eighty":-0.033773,"marketCap":10050282},{"date":"2023-03-31","current":-0.023609,"twenty":-1.928998,"median":-0.154441,"eighty":-0.033604,"marketCap":9971764},{"date":"2023-04-06","current":-0.021583,"twenty":-1.928151,"median":-0.149132,"eighty":-0.033224,"marketCap":9108068},{"date":"2023-04-14","current":-0.021102,"twenty":-1.927796,"median":-0.139109,"eighty":-0.032326,"marketCap":8911773},{"date":"2023-04-21","current":-0.020645,"twenty":-1.927008,"median":-0.136903,"eighty":-0.032054,"marketCap":8715479},{"date":"2023-04-28","current":-0.018737,"twenty":-1.926255,"median":-0.133541,"eighty":-0.031127,"marketCap":7851783},{"date":"2023-05-05","current":-0.012233,"twenty":-1.92564,"median":-0.132085,"eighty":-0.030656,"marketCap":5136636},{"date":"2023-05-12","current":-0.010151,"twenty":-1.924934,"median":-0.129315,"eighty":-0.030422,"marketCap":4239962},{"date":"2023-05-17","current":-0.015525,"twenty":-1.924699,"median":-0.12872,"eighty":-0.030394,"marketCap":6438462},{"date":"2023-05-24","current":-0.01241,"twenty":-1.923847,"median":-0.127351,"eighty":-0.030312,"marketCap":5104444},{"date":"2023-06-06","current":-0.011294,"twenty":-1.923229,"median":-0.127082,"eighty":-0.030287,"marketCap":4601144},{"date":"2023-06-23","current":-0.01166,"twenty":-1.921377,"median":-0.126789,"eighty":-0.029623,"marketCap":4711077},{"date":"2023-06-30","current":-0.010029,"twenty":-1.921221,"median":-0.126228,"eighty":-0.029556,"marketCap":4013046},{"date":"2023-07-07","current":-0.010029,"twenty":-1.919653,"median":-0.124609,"eighty":-0.028693,"marketCap":4011475},{"date":"2023-07-12","current":-0.009839,"twenty":-1.918319,"median":-0.124133,"eighty":-0.028553,"marketCap":3984779},{"date":"2023-07-21","current":-0.008368,"twenty":-1.91375,"median":-0.121995,"eighty":-0.028166,"marketCap":3384118},{"date":"2023-07-28","current":-0.009713,"twenty":-1.912037,"median":-0.11887,"eighty":-0.026558,"marketCap":3929825},{"date":"2023-08-04","current":-0.009982,"twenty":-1.909343,"median":-0.117384,"eighty":-0.025968,"marketCap":4042883},{"date":"2023-08-11","current":-0.063124,"twenty":-1.906409,"median":-0.115148,"eighty":-0.025993,"marketCap":13214071},{"date":"2023-08-18","current":-0.056265,"twenty":-1.905085,"median":-0.111944,"eighty":-0.026014,"marketCap":11659474},{"date":"2023-08-25","current":-0.040431,"twenty":-1.904385,"median":-0.109246,"eighty":-0.026167,"marketCap":8394821},{"date":"2023-09-01","current":-0.039579,"twenty":-1.903063,"median":-0.107257,"eighty":-0.026558,"marketCap":8239361},{"date":"2023-09-08","current":-0.030164,"twenty":-1.902079,"median":-0.104191,"eighty":-0.026916,"marketCap":6218386},{"date":"2023-09-15","current":-0.04193,"twenty":-1.899271,"median":-0.102845,"eighty":-0.027374,"marketCap":8705740},{"date":"2023-09-22","current":-0.034966,"twenty":-1.893257,"median":-0.099135,"eighty":-0.02807,"marketCap":7228874},{"date":"2023-09-29","current":-0.034571,"twenty":-1.892684,"median":-0.093499,"eighty":-0.028136,"marketCap":7154253},{"date":"2023-10-06","current":-0.031555,"twenty":-1.890304,"median":-0.081333,"eighty":-0.028263,"marketCap":6529305},{"date":"2023-10-13","current":-0.030714,"twenty":-1.88724,"median":-0.07903,"eighty":-0.028305,"marketCap":6356745},{"date":"2023-10-20","current":-0.027124,"twenty":-1.884852,"median":-0.078297,"eighty":-0.028205,"marketCap":5602766},{"date":"2023-10-27","current":-0.028607,"twenty":-1.883153,"median":-0.076024,"eighty":-0.028158,"marketCap":5907467},{"date":"2023-11-03","current":-0.03162,"twenty":-1.875108,"median":-0.073429,"eighty":-0.02823,"marketCap":6529305},{"date":"2023-11-10","current":-0.028477,"twenty":-1.870637,"median":-0.069813,"eighty":-0.02823,"marketCap":5907467},{"date":"2023-11-16","current":-0.03539,"twenty":-1.865237,"median":-0.069098,"eighty":-0.028106,"marketCap":7384333}],"updateTime":1743413215643}}}